<DOC>
	<DOC>NCT00399477</DOC>
	<brief_summary>Patients with Parkinson's Disease (PD) will be divided into 2 groups at each study center at their first visit based on the drugs they are taking for their PD: - Group 1 Patients using Azilect and no other therapy. - Group 2 Azilect in combination with other medications like Levodopa, Mirapex, or Requip.</brief_summary>
	<brief_title>A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Rasagiline</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Ropinirole</mesh_term>
	<criteria>1. Idiopathic Parkinson's disease. Diagnosis previously confirmed by the presence of bradykinesia and by at least one additional cardinal sign (i.e., resting tremor, rigidity), without other known or suspected cause of parkinsonism. 2. Requiring therapy for PD symptom control Azilect monotherapy. Azilect as adjunct therapy.. 1. Patients previously exposed to Azilect 2. Patients with pheochromocytoma 3. Concomitant MAO inhibitors or medications contraindicated for use with MAO inhibitors are not allowed.</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>